Carole Sable

Carole Sable

Director/Board Member at BASILEA PHARMACEUTICA AG

Net worth: - $ as of 30/05/2026

64 year
Health Technology
Consumer Services

Profile

Carole A. Sable is currently an Independent Non-Executive Director at Basilea Pharmaceutica AG since 2023.
Former positions include Executive Director-Clinical Research at Merck & Co., Inc. from 1995 to 2007, Vice President at Merck & Co., Inc. from 2010 to 2013, Chief Medical Officer at Vitae Pharmaceuticals LLC in 2016, Assistant Professor at the University of Virginia from 1993 to 1995, Chief Medical Officer at SCYNEXIS, Inc. from 2014 to 2015, Chief Medical Officer at Novexel SA from 2009 to 2010, Head-Clinical Development at Antabio SAS from 2018 to 2021, and Chief Medical Officer at Revolution Medicines, Inc. from 2015 to 2016.
Education includes a doctorate from Thomas Jefferson University, a doctorate from Sidney Kimmel Medical College conferred in 1983, and an undergraduate degree from the University of Scranton.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/12/2025 0 ( -.--% ) - $ 30/05/2026

Carole Sable active positions

CompaniesPositionStart
BASILEA PHARMACEUTICA AG Director/Board Member 26/04/2023

Former positions of Carole Sable

CompaniesPositionEnd
Chief Tech/Sci/R&D Officer 31/12/2020
VITAE PHARMACEUTICALS INC Chief Tech/Sci/R&D Officer 31/10/2016
REVOLUTION MEDICINES, INC. Chief Tech/Sci/R&D Officer 31/12/2015
SCYNEXIS, INC. Chief Tech/Sci/R&D Officer 19/02/2015
MERCK & CO., INC. Corporate Officer/Principal 31/12/2012
See the detail of Carole Sable's experience

Training of Carole Sable

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

84

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!